A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression

[1]  Mark J. P. Chaisson,et al.  Resolving the complexity of the human genome using single-molecule sequencing , 2014, Nature.

[2]  A. Roses,et al.  African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles , 2014, Alzheimer's & Dementia.

[3]  A. Roses,et al.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. , 2014, Human molecular genetics.

[4]  Michael W. Lutz,et al.  The cis-regulatory effect of an Alzheimer’s disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes , 2014, Alzheimer's & Dementia.

[5]  A. Verma.  Tale of two diseases: amyotrophic lateral sclerosis and frontotemporal dementia. , 2014, Neurology India.

[6]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[7]  Yaniv Erlich,et al.  The landscape of human STR variation , 2014, bioRxiv.

[8]  Patrick G. Shaw,et al.  C9orf72 Nucleotide Repeat Structures Initiate Molecular Cascades of Disease , 2014, Nature.

[9]  Edwin Smith,et al.  Enhancer biology and enhanceropathies , 2014, Nature Structural &Molecular Biology.

[10]  L. Tan,et al.  The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations , 2013, Journal of the Neurological Sciences.

[11]  D. Cleveland,et al.  Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis , 2013, Neuron.

[12]  Hiroshi Kimura,et al.  Histone modifications for human epigenome analysis , 2013, Journal of Human Genetics.

[13]  Mark Gerstein,et al.  The origin, evolution, and functional impact of short insertion–deletion variants identified in 179 human genomes , 2013, Genome research.

[14]  A. El-Osta,et al.  Transcriptional regulation by the Set7 lysine methyltransferase , 2013, Epigenetics.

[15]  A. Roses,et al.  Using Genetics to Enable Studies on the Prevention of Alzheimer's Disease , 2013, Clinical pharmacology and therapeutics.

[16]  Natalie de Souza.  The ENCODE project , 2012, Nature Methods.

[17]  Natalie de Souza.  Genomics: The ENCODE project , 2012, Nature Methods.

[18]  E. Pennisi.  Genomics. ENCODE project writes eulogy for junk DNA. , 2012, Science.

[19]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[20]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[21]  D. Hernandez,et al.  Genome-wide association study confirms extant PD risk loci among the Dutch , 2011, European Journal of Human Genetics.

[22]  V. Bansal,et al.  The importance of phase information for human genomics , 2011, Nature Reviews Genetics.

[23]  D. Galasko,et al.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. , 2010, Archives of neurology.

[24]  Matti Pirinen,et al.  Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 , 2010, Human molecular genetics.

[25]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[26]  A D Roses,et al.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease , 2009, The Pharmacogenomics Journal.

[27]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[28]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[29]  Jeffrey N. Browndyke,et al.  Genetic Regulation of α-Synuclein mRNA Expression in Various Human Brain Tissues , 2009, PloS one.

[30]  Nicholas W. Wood,et al.  Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy , 2009, PloS one.

[31]  D. Ge,et al.  Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain , 2009, Human molecular genetics.

[32]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[33]  K. Frazer,et al.  Human genetic variation and its contribution to complex traits , 2009, Nature Reviews Genetics.

[34]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[35]  M. Farrer,et al.  Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population , 2008, Acta neurologica Scandinavica.

[36]  M. Farrer,et al.  α-Synuclein and Parkinson disease susceptibility , 2007, Neurology.

[37]  William Stafford Noble,et al.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.

[38]  M. Farrer,et al.  Familial genes in sporadic disease: Common variants of α-synuclein gene associate with Parkinson's disease , 2007, Mechanisms of Ageing and Development.

[39]  R. Nussbaum,et al.  Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.

[40]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[41]  H. Inoko,et al.  Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. , 2006, Human molecular genetics.

[42]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[43]  P. Rorsman,et al.  Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels. , 2005, Genome research.

[44]  T. Meitinger,et al.  Multiple regions of α‐synuclein are associated with Parkinson's disease , 2005, Annals of neurology.

[45]  R. Nussbaum,et al.  Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. , 2005, American journal of human genetics.

[46]  Paul T. Groth,et al.  The ENCODE (ENCyclopedia Of DNA Elements) Project , 2004, Science.

[47]  M. Farrer,et al.  α‐Synuclein promoter confers susceptibility to Parkinson's disease , 2004 .

[48]  G. Cutting,et al.  A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Nussbaum,et al.  Functional analysis of intra-allelic variation at NACP-Rep1 in the α-synuclein gene , 2003, Human Genetics.

[50]  H. Soininen,et al.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. , 2003, Journal of neuropathology and experimental neurology.

[51]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[52]  R. Nussbaum,et al.  Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. , 2001, Human molecular genetics.

[53]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[54]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[55]  M. Oda,et al.  Genetic studies in Parkinson's disease with an α-synuclein/NACP gene polymorphism in Japan , 2001, Neuroscience Letters.

[56]  J. Jankovic,et al.  Polymorphism of NACP-Rep1 in Parkinson’s disease: An etiologic link with essential tremor? , 2000, Neurology.

[57]  H Yonas,et al.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.

[58]  A. Kimura,et al.  Transcriptional regulation of the human type I collagen alpha2 (COL1A2) gene by the combination of two dinucleotide repeats. , 1999, Gene.

[59]  I G McKeith,et al.  Report of the second dementia with Lewy body international workshop , 1999, Neurology.

[60]  Y. Sasaguri,et al.  Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.

[61]  R. Krüger,et al.  Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.

[62]  J. Blackwell,et al.  Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility , 1999, Journal of medical genetics.

[63]  K. Lesch,et al.  A promoter-associated polymorphic repeat modulates PAX-6 expression in human brain. , 1998, Biochemical and biophysical research communications.

[64]  S. Mirra.  The CERAD Neuropathology Protocol and Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease: A Commentary , 1997, Neurobiology of Aging.

[65]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[66]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1990, Neurology.

[67]  M. Farrer,et al.  alpha-Synuclein and Parkinson disease susceptibility. , 2007, Neurology.

[68]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[69]  M. Farrer,et al.  alpha-Synuclein promoter confers susceptibility to Parkinson's disease. , 2004, Annals of neurology.

[70]  R. Nussbaum,et al.  Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. , 2003, Human genetics.

[71]  D. Hernandez,et al.  alpha-Synuclein gene haplotypes are associated with Parkinson's disease. , 2001, Human molecular genetics.

[72]  M. Oda,et al.  Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. , 2001, Neuroscience letters.

[73]  L. Hansen.  The Lewy body variant of Alzheimer disease. , 1997, Journal of neural transmission. Supplementum.

[74]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.